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Abstract Limited information is available regarding the
role of endogenous Glial cell line-derived neurotrophic
factor (GDNF) in the spinal cord following transection
injury. The present study investigated the possible role of
GDNF in injured spinal cords following transection injury
(T9–T10) in adult rats. The locomotor function recovery of
animals by the BBB (Basso, Beattie, Bresnahan) scale
score showed that hindlimb support and stepping function
increased gradually from 7 days post operation (dpo) to
21 dpo. However, the locomotion function in the hindlimbs
decreased effectively in GDNF-antibody treated rats.
GDNF immunoreactivty in neurons in the ventral horn of
the rostral stump was stained strongly at 3 and 7 dpo, and
in the caudal stump at 14 dpo, while immunostaining in
astrocytes was also seen at all time-points after transection
injury. Western blot showed that the level of GDNF protein
underwent a rapid decrease at 7 dpo in both stumps, and
was followed by a partial recovery at a later time-point,
when compared with the sham-operated group. GDNF
mRNA-positive signals were detected in neurons of the
ventral horn, especially in lamina IX. No regenerative
ﬁbers from corticospinal tract can be seen in the caudal
segment near the injury site using BDA tracing technique.
No somatosensory evoked potentials (SEP) could be
recorded throughout the experimental period as well. These
ﬁndings suggested that intrinsic GDNF in the spinal cord
could play an essential role in neuroplasticity. The mech-
anism may be that GDNF is involved in the regulation of
local circuitry in transected spinal cords of adult rats.
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Introduction
Spinal cord injury (SCI), a common result of car accidents,
high-altitude falls and crashes, and other violent injuries is
increasing yearly. It has been reported that there are about
15–40 traumatic SCI cases per million persons annually
population worldwide [1]. Once the spinal cord is dam-
aged, it usually results in severe neurologic dysfunction
and disability. Over the past several years, many extensive
experiments have been done in order to ﬁnd a way to
promote the repair of the injured spinal cord. However, no
good therapeutic approaches have yet been found.
Recently, it has been shown that delivery of exogenous
neurotrophic factors (NTFs) to the injured spinal cord has
beneﬁcial effects in improving functional recovery [2],
indicating the potential value of NTFs in the treatment of
SCI.
Glial cell line-derived neurotrophic factor (GDNF), a
distant member of the transforming growth factor-b
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DOI 10.1007/s11064-007-9536-1(TGF-b) family, was originally puriﬁed using an assay
based on its ability to maintain the survival and function
of embryonic ventral midbrain dopaminergic neurons in
vitro [3]. GDNF supports neural survival in several neu-
ronal populations, including midbrain dopamine neurons
and motoneurons in the central nervous system. It pro-
motes the survival and the differentiation of many
peripheral neurons, such as sympathetic, parasympathetic,
and sensory neurons [3–10]. Following injury, GDNF
showed a beneﬁt effect to rescue motoneurons degenera-
tion after spinal root avulsion and distal nerve axotomy
[11], promotion of axonal regeneration [12] and enhanc-
ing regeneration of dorsal roots (DR) into the adult rat
spinal cord [13]. In addition, the transplantation of
GDNF-producing cells greatly enhances the survival of
spinal cord motorneurons [11, 14, 15] and regeneration
of several spinal systems, including dorsal column sen-
sory, and regionally projecting propriospinal pathways
[16, 17] after SCI. The biological action of GDNF is
mediated by a two-component receptor GFRa-1 and
protein tyrosine kinase Ret [18–21]. The GFRa-1 recep-
tors expressed on a variety of neurons that project into the
spinal cord, including supraspinal neurons, dorsal root
ganglia, and local neurons. GDNF mRNAs are widely
distributed in a variety of neuronal and non-neuronal
tissues of embryos and adults [4, 22–25].
Although exogenous GDNF is available partially to
promote propriospinal axonal regeneration and loco-
motion functional recovery, the role of intrinsic GDNF
in injured spinal cords is largely unknown. Therefore,
the present study investigated the possible role of
GDNF at various time intervals following spinal cord
t r a n s e c t i o ni n j u r yi na d u l tr a t s ,s oa st og a i ni n s i g h t s
into the contribution of endogenous GDNF in spinal
neuroplasticity.
Materials and methods
Characterization of antibodies
To localize GDNF protein in the spinal cord, an afﬁnity-
puriﬁed rabbit polyclonal antibody (D-20, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) was used in this
study. The speciﬁcity of antibody for GDNF was con-
ﬁrmed by Western blots using rat spinal cord
homogenates.
Preparation of probe for in situ hybridization
For detection of GDNF cellular expression in situ, we used
Digoxigenin-labeled oligonucleotide probe designed by
Primerpremier5.0packagewhichwascomplementarytothe
rats GDNF gene sequence (33 mer, 50-GCCCTACTTTGT
CAC–TCACCAGCCTTCTATTTC-30). This antisense
DNAsingle-strandedoligonucleotideprobewassynthesized
by Takara Biotechnology Company.
Animal grouping and surgery
Sixty-ﬁve adult Sprague-Dawley rats of either sex
(weighing 200–220 g) were obtained from the Animal
Experiment Center of Sichuan University of Medical
Sciences. Fifty rats among all animals, designated as
sham-operated group and spinal cord transection group
that animals were allowed to survive 3, 7, 14 and 21 days
post operation (dpo), were used for immunohistochemis-
try and in situ hybridization (n = 5 in each group), and
Western blot analysis (n = 5 in each group) respectively.
Another ﬁve rats were intraperitoneally injected anti-
GDNF solution (2.5 ml/kg) once every 2 days until
21 dpo, designed as antibody neutralization group. Five
animals, subjected to cord transaction, were injected with
distilled water as the distilled water group. The last ﬁve
operated rats were used to investigate corticospinal tract
sprouting. Every effort was taken to reduce the number of
animals and suffering during the experiments. All the
experiments using animals were carried out according to
the guidelines of the NIH Guide for Care and Use of
Laboratory Animal. For the cord transection operation,
the rats were anesthetized with 3.6% Chloral Hydrate
(1 ml/100 g). A midline incision was made in the back,
then the T7–T8 spinous processes and the vertebral lam-
inae were removed to expose the spinal cord at T9–T10
level. The cord was transected between T9 and T10 seg-
ments with a pair of microscissors. After surgery, the
superﬁcial back muscles and the skin were sutured along
the midline.
Behavior tests
All rats in each group were evaluated using the BBB
(Basso, Beattie, Bresnahan) scale score [26]. The BBB
score for evaluation of hindlimbs function after transected
injury ranges from zero, which corresponds to ﬂaccid
paralysis, to 21, which is normal gait. Animals were
allowed to walk around freely in a circular ﬁeld (1.2 m in
diameter) for 4 min while movements of the hindlimbs
were closely observed. Ranking according to the scoring
system described by Basso et al. [26] includes frequency
and quality of hindlimb movement as well as forelimb/
hindlimb coordination.
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(SEP)
The right peroneal nerve of the rats was dissected and a
stimulation electrode was placed on it while a hole (3–
4 mm in diameter) was made on the skull (2 mm to the
left of the midline and 2 mm in front of the fonticulus
posterior). An electrode was placed on the dura of brain
cortex to record the SEP. The reference electrode was
inserted at the nose epithelium. A ground electrode was
inserted at the tail. The stimulus intensity was set high
enough to produce a marked muscle twitch in the hind
limb, about 1.1 mA, the amplitude was 0.2 ms and the
frequency 3 Hz. The SEP Tracings represented the aver-
age of 200 responses.
Immunohistochemistry
After anesthesia with 3.6% Chloral Hydrate (1 ml/100 g),
rats were perfused with 500 ml of cold phosphate-buf-
fered saline (PBS) for 5 min and 500 ml cold 4%
paraformaldehyde solution for 30 min. The T9 and T10
spinal cord segments in the sham-operated group, and the
cord stumps rostral and caudal to the injury site in the
experimental group were harvested. This was followed by
a postﬁx for 6–12 h, then immersed in 0.1 M PBS con-
taining 20% sucrose overnight. Sections of 20 lm
thickness were cut on a freezing microtome and used for
freeﬂoating GDNF immunostaining, then rinsed with
0.01 M PBS and soaked in PBS containing 3% H2O2 for
30 min at room temperature to quench the endogenous
peroxidase activity. They were immersed in PBS con-
taining 5% goat serum and 0.3% TritonX-100 solution at
room temperature for 2 h, then incubated at 4C for 24 h
with anti-GDNF (1:1,000, Chemicon) rabbit polyclonal
antibody. Sections were incubated with biotinylated goat
anti-rabbit IgG antibody (1:100 dilution) for 1.5 h at room
temperature, and by reaction with avidin-biotinylated
peroxidase complexes (1:250, ABC Elite, Vector Labs).
GDNF immunoreactivity was visualized with brown
staining using diaminobenzidine (DAB) and H2O2 as
substrate for 5 min, and observed with a light microscope.
Negative control experiments in which PBS was substi-
tuted for the primary antibody were performed to
ascertain the speciﬁcity of antibody staining.
In situ hybridization
Sections from sham-operated rats of 25 lm thickness
were also cut on a freezing microtome and used for
in situ hybridization. Sections were ﬁxed in 4%
paraformaldehyde in 0.1 M PBS, pH 7.2 (all treatments
were performed at room temperature unless otherwise
indicated), and further treated with 0.3% TritonX-100
solution for 10 min and proteinase K (5 lg/ml) at 37C
for 25 min, reﬁxed with 4% paraformaldehyde for
5 min, repeatedly immersed in 0.1 M PBS, then acety-
lated with 0.25% acetic anhydride in 0.1 M trieth-
anolamine (pH 8.0) to prevent non-speciﬁc binding of the
probes. The sections were washed with 29 SSC (pH 7.0)
and then prehybridized in a hybridization solution (50%
formamide, 10% dextran sulfate, 19 Denhardt’s solution,
0.2 mg/ml Herring sperm DNA, and 10 mM dithiothrei-
tol) without probes at 37C for 2 h before hybridization,
then hybridized in 100 ll hybridization solution contain-
ing 1 ll probes at 37C for 12–16 h in a moist chamber.
This was followed by washing in decreasing concentra-
tions of SSC, from 49 SSC (pH 7.0) at 37C for 20 min,
29 SSC (pH 7.0) at 42C for 20 min, 19 SSC (pH 7.0) at
48C for 20 min and ending with 0.59 SSC (pH 7.0) at
50C for 20 min. Then sections were incubated at 37Ci n
1% blocking buffer (Roche) for 1 h, subsequently reacted
in 1:1,000 sheep anti-digoxygenin-alkaline phosphatase
(AP) antibody in 1% blocking buffer at 4C overnight.
Lastly, AP activity was detected using nitroblue tetrazo-
lium (NBT)/5-bromo-4-chloro-3-indolyl phosphate (BCIP)
substrate (Roche). The sections were visualized with blue
and purple sedimentation then observed with a light
microscope.
GFAP/GDNF double-label immunohistochemistry
Two-color immunohistochemical staining for simulta-
neous detection of glial ﬁbrillary acidic protein (GFAP)/
GDNF expression was performed as described above.
Brieﬂy, sections were stained with anti-GDNF rabbit
polyclonal antibody (1:1,000), and using DAB solutions
as a substrate. This was followed by second incubation
with anti-GFAP rabbit polyclonal antibody (1:1,000,
AB5804, Chemicon), and ﬁnally, reacted with TMB
solutions. Double labeling showed a combination of
brown and blue product.
Western blotting
The spinal cord from the rostral and caudal stumps was
obtained. After carefully removing the spinal meninges, the
cords were homogenized on ice in a Lysis Buffer con-
taining 0.05 M Tris–HCl (pH 7.4, Amresco), 0.5 M EDTA
(Amresco), 30% TritonX-100 (Amresco), NaCl (Amresco),
10% SDS (Sigma) and 1 mM PMSF (Amresco), then
centrifuged at 12,000g for 30 min. The supernatant was
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123obtained and stored at -80C for late use. Protein con-
centration was assayed with BCA reagent (Sigma, St.
Louis, MO, USA). A 20 ll aliquot of the samples was
loaded on to each lane and electrophoresed on 12% SDS-
polyacrylamide gel (SDS-PAGE) for 2.5 h at a constant
voltage of 120 V. Proteins were transferred from the gel to
a nitrocellulose membrane for 435 min at 24 V. The
membrane was blocked with phosphate-buffered saline
containing 0.05% Tween-20 (PBST) with 10% non-fat dry
milk overnight at 4C. The membrane was rinsed with
PBST and incubated with the primary antibody for GDNF
(1:1,000) at 4C. The membrane was incubated with a
HRP-conjugated goat anti-rabbit IgG (1:5,000; Vector
Laboratories, CA) for 2 h at room temperature. The
membrane was developed in ECM kit and exposed against
X-ray ﬁlm in a darkroom. Densitometry analysis for the
level of GDNF protein was performed by Bio-Gel Imag-
ining system equipped with Genius synaptic gene tool
software. b-actin (the primary antibody, 1:1,000, the sec-
ondary antibody, 1:2,000; Santa Cruz Biotechnology) was
used as an internal control.
BDA anterograde tracing
At 14 dpo, the animals for this part were anesthetized and
ﬁxed in a David Kopf Instruments (Tujunga, CA) stereo-
taxic head-holder device. Burr holes were made in the
dorsal cranium, and biotinylated dextran amine (BDA)
(10% BDA solution, Molecular Probes) was microinjected
into eight sites at a depth of 0.7 mm from the cortical
surface (0.5 ll/site) to cover the hindlimb region. Animals
were then sacriﬁced 2 weeks later to allow sufﬁcient time
for axonal transport of BDA in corticospinal tract. The
spinal cords were removed and postﬁxed at 3 days in cold
4% paraformaldehyde in 0.1 M PBS (pH 7.2). Transverse
sections (30 lm) of spinal cord at the injury site and
neighboring rostral and caudal parts to the injury site were
processed for the presence of BDA-labeled axons by
incubation in avidin-HRP (Molecular Probes). Lastly, DAB
stain was performed to visualize the positive ﬁber, as
brown color staining.
GDNF antibody neutralization
After 14 dpo, each rat was intraperitoneally injected with
0.5 ml (30 mg/ml, 30 mg of anti-GDNF diluted in 1 ml of
distilled water) anti-GDNF solution once every 2 days until
21 dpo. GDNF antibody was the distilled water replace as
control in another ﬁve rats. The locomotion in hindlimbs
by BBB score was evaluated at 3, 7, 14, and 21 dpo.
Statistical analysis
All data were expressed as the mean ± S.E.M. They were
analyzed using One-way ANOVA and LSD-q test by SPSS
software package. The statistical signiﬁcance was deﬁned
as P\0.05.
Results
Behavior tests
The BBB score for locomotor function in sham-operated
rats hindlimbs was 21. Compared with the sham-operation
group, the BBB score of animals in the group with only the
cord transection and distilled water group increased grad-
ually from 7 to 21 dpo. A signiﬁcant decrease in the BBB
score for the GDNF-antibody treated group was observed
(P\0.05) (Table 1).
Somatosensory evoked potentials (SEP)
Evoked potentials are the electrical signals generated by
the nervous system in response to sensory stimuli.
Somatosensory evoked potentials consist of a series of
waves that reﬂect sequential activation of neural structures
along the somatosensory pathways following electrical
stimulation of peripheral nerves. SEP (P1N1P2 type) was
recorded in the control rats and shown in Fig. 1.
Throughout the experimental period, no SEP could be
recorded in rats subjected to cord transection.
Table 1 Mean values of BBB scores in cord transected rats (mean ± S.E.M)
Group 3 Days 7 Days 14 Days 21 Days
Sham-operation group 5 ± 0.6 21 ± 02 1 ± 02 1 ± 0
Transection group 0 ± 0 0.8 ± 0.3 2.4 ± 0.7 3.6 ± 0.5
Distilled water group 0 ± 0 0.6 ± 0.7 2.0 ± 0.4 3.3 ± 0.3
GDNF-antibody treated group 0 ± 0 0.2 ± 0.4 0.6 ± 0.3 0.9 ± 0.5
BBB score in rats subjected to the sham operation was constant. Following transection injury, the BBB score of animals increased signiﬁcantly
from 7 to 21 dpo (P\0.05). There had no statistical signiﬁcance in BBB score between cord transection group and distilled water group
(P[0.05), while a signiﬁcant decrease of BBB score in GDNF-antibody treated group was observed (P\0.05)
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In the control group, GDNF immunoreactivity was
observed in the cytoplasm and nuclei of the neurons from
the ventral horn in the gray matter (Fig. 3a). Most of the
small and medium-sized neurons in the intermediate zone
and dorsal horn were stained faintly. GDNF positive pro-
ﬁles (Fig. 3b) simultaneously labeled with GFAP, were
present in the white matter (Fig. 2b). In the negative con-
trol group, no speciﬁc immunopositive staining was
detected (Fig. 2a).
In the rostral stump, strong immunostaining for GDNF
was observed in neurons from the ventral horn at 3 and
7 dpo (Fig. 3c, d; Table 2). Moderate to intense immuno-
stained neurons were seen at 14 and 21 dpo, as shown in
Figs. 3g, 4a and Table 2. In the white matter, astrocytes
showed strong immunoreactivity of GDNF from 3 to
21 dpo (Figs. 3d–f, 4b; Table 2).
In the gray matter of the caudal stump, moderately
immunostained neurons were detected at 3, 7 and 21 dpo,
and more so at 14 dpo (Fig. 4c–e, g; Table 2). The sub-
cellular localization for GDNF was observed both in
cytoplasm and nuclei at 21 dpo (Fig. 4g). At both 14 and
21 dpo, astrocytes in the white matter strongly stain with
GDNF immunoreactivity as shown in Fig. 4f, h and
Table 2.
Localization of GDNF mRNA in spinal cord of rats
Signals of hybridization for GDNF mRNA were markedly
detected in the Central canal and lamina III, IV and V, in
which small neurons were moderately NBT/BCIP stained
(Fig. 5a). Medium-sized neurons were seen in the ﬁeld
of the intermediomedial nucleus and nucleus dorsalis
(Fig. 5a). In the ventral horn, GDNF mRNA-positive large
neurons were also observed in lamina IX (Fig. 5b). A few
scattered glial cells were probe-labeled with light density in
white matter (Fig. 5c).
Western blotting
A single positive band was observed at a molecular weight
of about 34,000, which corresponds to the molecular
weight of GDNF.
In the rostral stump, the level of GDNF protein
increased at 3 dpo, when compared with the control group
(P\0.05), then decreased quickly to its lowest level at
7 dpo (P\0.05) which was less than that of the control
level, and then began to increase again at 14 dpo. How-
ever, GDNF protein was higher than what was seen in
the control group at 21 dpo (Figs. 6a, 7). In the caudal
stump, GDNF protein immediately decreased at 3 dpo,
reached its lowest level at 7 dpo (P\0.05), then increased
from 14 to 21 dpo, but it did not go back to the control
level (Figs. 6b, 7).
BDA tracing
BDA-positive axons which stained as brown silkiness were
detected in rostral cord sections of the injury site (Fig. 8a),
but not in the ﬁeld of scar tissue (Fig. 8b), and in the caudal
segment near the injury site (Fig. 8c).
Fig. 1 Somatosensory evoked potential was recorded in normal adult
rats (P1N1P2 type). The latency of SEP: P1 (10.3 ± 0.26) ms, N1
(8.81 ± 0.34) ms, P2 (15.5 ± 0.43) ms, amplitude: P1 (2.34 ± 0.02),
N1 (16.3 ± 0.14), P2 (-5.06 ± 0.05)
Fig. 2 In the negative control
group, no speciﬁc
immunopositive staining was
detected (a). GDNF positive
proﬁles, simultaneously label-
GFAP, were present in the white
matter (b)
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magniﬁcation (4009), GDNF
immunoreactivity (IR) was
observed in neurons from the
ventral horn of the gray matter
in the normal spinal cord (a,
arrow). GDNF (IR) in astrocytes
was also seen in white matter
(b, arrow). In the rostral stump,
strong GDNF IR was detected
in neurons from the ventral horn
at 3 and 7 dpo (c, e, 4009,
arrows). Moderate to intense
immunostained neurons were
labeled at 14 dpo (g, 4009,
arrow). Intensely
immunostained IR in astrocytes
of the white matter were
observed from 3 to 14 dpo (d, f,
h, 4009, arrows)
Table 2 GDNF immunostaining intensity in neurons and astrocytes
Normal 3 Days 7 Days 14 Days 21 Days
Neurons + +++ +++ ++*+++ ++*+++
Rostral part Astrocytes ++ +++ +++ +++ +++
Caudal part Neurons + +*++ ++ +++ ++
Astrocytes ++ ++ ++ +++ +++
Intensity: + weak, ++ moderate, +++ strong
Neurons in the ventral horn of the rostral stump was strongly stained for GDNF at 3 and 7 dpo, and in the caudal stump at 14 dpo. The GDNF
positive staining in astrocytes was also stronger at all time-points after transection injury than seen in control group
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In the present study, GDNF immunoreactive products in
neurons from the gray matter and in astrocytes from the
white matter of the spinal cord were observed in the sham-
operation group. This indicates that GDNF could be
involved in either the physiological function or the main-
tenance of survival for all kinds of neurons and astrocytes.
It has been shown that GDNF mRNAs widely distributed in
a variety of neuronal and non-neuronal tissues of embryos
and adults [4, 23–25]. In addition, GDNF mRNA positive
signals were found in the ventral horns, the ﬁeld of nucleus
dorsalis, and the dorsal horns in the spinal cords of adult
rats [2, 16, 27] and in the dorsal root ganglia in newborn
rats [23]. Therefore, it raised the possibility that GDNF was
synthesized by cells of the spinal cord and the GDNF
Fig. 4 In the rostral stump,
moderate to intense
immunostained neurons were
labeled at 21 dpo (a, 4009,
arrow). Intensely
immunostained IR in astrocytes
of the white matter were also
observed at 21 dpo (b, 4009,
arrow). In the caudal stump,
immunostained products were
detected in neurons of the gray
matter at 3 and 7 dpo
(c, d, 4009, arrows). Strong
immunostained IR for GDNF in
neurons was observed at 14 dpo
(e, 4009, arrow). Under higher
magniﬁcation, immunoreactive
structures of GDNF were
localized in both cytoplasm and
nuclei at 21 dpo (g, 4009,
arrow), GDNF IR in astrocytes
of the white matter was
intensely immunostained at 14
and 21 dpo (f, h, 4009, arrows)
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GDNF plays a potential role in both physiological and
pathological conditions.
Following cord transection, rats exhibited spinal cord
dysfunction throughout the experimental period. There was
an absence of SEP in surface recordings, indicating a loss
of sensory function in the hindlimbs following transection
injury. Comparatively, locomotion function recovery was
observed from 7 to 21 dpo, which was parallel to the
improvement in BBB score. It showed that locomotor
functional plasticity in the hindlimbs of rats did occur
following SCI. As corticospinal tract regeneration was not
seen in the caudal part near the injury site and scar tissues,
it appears impossible to reestablish connectivity between
the areas rostral and caudal of the injury site. The possible
reason for locomotor function improvement may be related
to the modulation of spinal circuit activity from endoge-
nous neurotrophins. In the present study, BBB scores in the
GDNF-antibody treated rats was inferior to that of the
group not receiving the antibody treatment, indicating
intrinsic GDNF may be available for improving locomotor
function recovery to some extent in the hindlimbs of rats
[15, 28]. It has been reported that GDNF can promote the
repair or survival of spinal motoneurons [4, 7, 29–32].
Several other studies have shown that the administration of
GDNF could promote axonal regeneration, and enhance
locomotion functional recovery [2, 15, 30, 33–36].
GDNF immunoreactivity products in neurons from the
ventral horn of the rostral stump were strongly stained at 3
and 7 dpo, and in the caudal stump at 14 dpo, suggesting
that the GDNF expression in neurons was up-regulated
following injury. This may be related to the locomotion
functional recovery of hindlimbs. Glazner et al. [37]
showed that strong labeling for GDNFR-a and c-ret
mRNA was observed in large neurons from the ventral
horn. Our results also supported the mRNA expression for
GDNF in neurons of the ventral horn, as well as astrocytes
in white matter using in situ hybridization. RET expres-
sion was unregulated following peripheral axotomy in
Fig. 5 In the spinal cord of adult rats, GDNF mRNA-positive
product were markedly detected in neurons from the lamina III, IV
and V and the central canal (a). Medium-sized neurons were seen in
the ﬁeld of intermediomedial nucleus and Nucleus dorsalis. In the
ventral horn, GDNF mRNA-positive large neurons were also
observed in lamina IX. Under higher magniﬁcation (2009), positive
products with blue and purple staining were localized in the
cytoplasm (b, arrows), also in white matter scattered glial cells were
probe-labeled with light density (c, arrows)
Fig. 6 In the rostral stump, GDNF protein level increased at 3 dpo
(P\0.05), then reached its lowest point at 7 dpo which was below
the control group (P\0.05), then began to recover at 14 dpo, but it
was less than that of normal level. This was followed by a continuous
increase higher than the control group at 21 dpo (a). In the caudal
stump, GDNF protein decreased at 3 dpo, reached its lowest point at
7 dpo (P\0.05), then started to increase at 14 dpo, but it was lower
than the normal level at 21 dpo (b)
Fig. 7 GDNF levels were signiﬁcantly different from each other
(P\0.05), except for the comparison between the 21 dpo and normal
group, as well as the 21 and 3 dpo group in the rostral stump. The
groups were signiﬁcantly different from each other (P\0.05), except
for the comparison between the 3 and 14 dpo group in the caudal
stump
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30 min after SCI signiﬁcantly improved motor function
and reduced blood–spinal cord barrier (BSCB) breakdown,
edema formation, and cell injury at 5 h has been reported
[39]. Therefore, GDNF is available to assist in locomotion
functional plasticity by exerting behavioral and anatomic
neuroprotection following SCI.
In the present study, the expression patterns of endog-
enous GDNF indicated its possible role in maintaining
motorneuron survival because GDNF mRNA-positive
products were detected in neurons from the ventral horn by
in situ hybridization. Of course, GDNF retrograde axonal
transport from a target tissue to neuronal cell bodies [40,
41] is not absolutely excluded. It has been reported that
GDNF produced by skeletal muscle is taken up at the nerve
terminals and retrogradely transported to motoneurons of
the ventral horn by axons [30].
Comparing the results of immunostaining, the GDNF
level varied throughout the spinal cord at 3 dpo. In the
caudal stump, GDNF showed a signiﬁcant decrease. This
was probably due to the transection injury that triggers a
process destructive to ascending and descending tracts
conduction and that extends tissue loss. Differently, a rapid
up-regulation of GDNF was observed in the rostral stump.
This suggested that GDNF had accumulated around the
transection site due to interruption of its transport within
the axons. Satake et al. [42] reported GDNF transcription
began to increase within 30 min after injury and peaked
within 3 h after spinal cord contusion injury. Interestingly,
the level of GDNF protein reached its lowest point at 7 dpo
in both stumps, probably due to the consequences of cell
death or apoptosis and/or interruption of the spinal cord
pathways. Subsequently, GDNF protein levels gradually
started to recover and surpassed the control level in the
rostral stumps at 21 dpo, which may be explained by (1)
GDNF transport within axons was strengthened, (2)
inﬂammation leads to the increase of GDNF synthesis [36],
and (3) induction of de novo synthesis of GDNF by neu-
rons and/or non-neuronal cells.
Noticeably, the GDNF positive cells in the white matter
were labeled by GFAP simultaneously, which identiﬁed the
labeled cells as astrocytes. Indeed, an association between
reactive astrocytes and regenerating nerve ﬁbers in the
white matter of the central nervous system in vivo has been
reported [43, 44]. Also, increased GFR-1 in astrocytes of
degenerating white matter in adult rat spinal cords after
mechanical injury has been shown [2]. These results indi-
cated that GDNF expression in astrocytes may be involved
in neuroplasticity following spinal cord transection injury.
The present study provides new evidence to understand
the role of intrinsic GDNF in the rostral and caudal stumps
of injured spinal cords. It suggests that GDNF plays an
essential role in the neuroplasticity of the local circuitry,
especially in the caudal stump of the transected spinal
cords.
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